EyePoint (EYPT) Long-Term Deferred Tax (2017 - 2018)
EyePoint (EYPT) reported Long-Term Deferred Tax of $6.2 million for Q2 2018, down 80.32% on a YoY basis from $31.5 million in Q2 2017, and down 71.16% sequentially from $21.5 million in Q4 2017.
EyePoint (EYPT) Long-Term Deferred Tax (2017 - 2018) Analysis & Trends
EyePoint (EYPT) has 2 years of Long-Term Deferred Tax data on file, last reported at $6.2 million in Q2 2018.
- For the quarter ending Q2 2018, Long-Term Deferred Tax fell 80.32% year-over-year to $6.2 million; the trailing twelve-month figure through Jun 2018 stood at $6.2 million (down 80.32% YoY), and the FY2018 full-year result was $6.2 million, down 80.32% from the prior year.
- Long-Term Deferred Tax eased to $6.2 million in Q2 2018, from $21.5 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $31.5 million in Q2 2017 to a low of $6.2 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 6.20 Mn |
| Dec 31, 2017 | 21.50 Mn |
| Jun 30, 2017 | 31.50 Mn |